Mono-chemotherapy

DRUG3 trials

Sponsors

Swiss Cancer Institute, Zhejiang University, Peking University Third Hospital

Conditions

Advanced Pancreatic CancerBreast CancerIntrahepatic Cholangiocarcinoma by AJCC V8 Stage

Phase 2

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Zhejiang UniversityIntrahepatic Cholangiocarcinoma by AJCC V8 Stage

Start: 2020-04-22End: 2024-04-22Target: 120Updated: 2020-06-04

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Not yet recruitingNCT06422156

Peking University Third HospitalAdvanced Pancreatic Cancer

Start: 2024-06-01End: 2026-06-01Target: 73Updated: 2024-05-20

Phase 3

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

TerminatedNCT03905343

Swiss Cancer InstituteBreast Cancer

Start: 2019-06-25End: 2021-04-15Updated: 2021-06-16

Related Papers

Abstract OT-37-01: Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18

Cancer Research2021-02-15